Taysha Gene Therapies (NASDAQ:TSHA) Upgraded to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Taysha Gene Therapies (NASDAQ:TSHA) from a sell rating to a hold rating in a research report released on Saturday morning.

Several other research firms also recently weighed in on TSHA. Wells Fargo & Company lifted their price target on shares of Taysha Gene Therapies from $8.00 to $11.00 and gave the company an “overweight” rating in a research note on Monday, January 5th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Taysha Gene Therapies in a research report on Monday, December 29th. Raymond James Financial reiterated a “strong-buy” rating and issued a $13.00 target price on shares of Taysha Gene Therapies in a report on Tuesday, January 6th. Needham & Company LLC boosted their target price on shares of Taysha Gene Therapies from $10.00 to $12.00 and gave the stock a “buy” rating in a research report on Thursday. Finally, UBS Group set a $11.00 target price on shares of Taysha Gene Therapies in a report on Thursday, December 4th. One investment analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Taysha Gene Therapies currently has a consensus rating of “Moderate Buy” and a consensus target price of $11.09.

Taysha Gene Therapies Stock Performance

Shares of TSHA stock opened at $4.40 on Friday. The firm has a 50 day moving average of $4.63 and a 200-day moving average of $4.56. The company has a market cap of $1.21 billion, a price-to-earnings ratio of -12.94 and a beta of 1.02. The company has a quick ratio of 10.48, a current ratio of 10.48 and a debt-to-equity ratio of 0.23. Taysha Gene Therapies has a 52 week low of $1.05 and a 52 week high of $6.02.

Taysha Gene Therapies (NASDAQ:TSHA) last released its earnings results on Thursday, March 19th. The company reported ($0.08) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.03. The company had revenue of $5.49 million for the quarter, compared to the consensus estimate of $1.89 million. Taysha Gene Therapies had a negative net margin of 1,144.97% and a negative return on equity of 62.55%. On average, equities analysts forecast that Taysha Gene Therapies will post -0.35 earnings per share for the current year.

Insider Buying and Selling

In related news, CFO Kamran Alam sold 23,849 shares of Taysha Gene Therapies stock in a transaction on Monday, January 26th. The stock was sold at an average price of $4.61, for a total transaction of $109,943.89. Following the sale, the chief financial officer directly owned 1,443,786 shares in the company, valued at approximately $6,655,853.46. This trade represents a 1.62% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Sukumar Nagendran sold 26,918 shares of the business’s stock in a transaction on Monday, January 26th. The stock was sold at an average price of $4.61, for a total value of $124,091.98. Following the completion of the transaction, the insider directly owned 1,317,389 shares in the company, valued at approximately $6,073,163.29. This represents a 2.00% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 598,623 shares of company stock worth $2,822,188. 3.78% of the stock is owned by company insiders.

Institutional Trading of Taysha Gene Therapies

A number of large investors have recently added to or reduced their stakes in the stock. Vestal Point Capital LP lifted its stake in Taysha Gene Therapies by 150.0% in the fourth quarter. Vestal Point Capital LP now owns 13,750,000 shares of the company’s stock valued at $75,625,000 after purchasing an additional 8,250,000 shares during the last quarter. Goldman Sachs Group Inc. raised its stake in shares of Taysha Gene Therapies by 2.3% in the fourth quarter. Goldman Sachs Group Inc. now owns 13,692,739 shares of the company’s stock valued at $75,310,000 after buying an additional 309,031 shares during the period. Vanguard Group Inc. lifted its position in shares of Taysha Gene Therapies by 3.3% during the 4th quarter. Vanguard Group Inc. now owns 13,267,805 shares of the company’s stock valued at $72,973,000 after buying an additional 418,192 shares during the last quarter. Octagon Capital Advisors LP lifted its position in shares of Taysha Gene Therapies by 17.7% during the 2nd quarter. Octagon Capital Advisors LP now owns 12,592,500 shares of the company’s stock valued at $29,089,000 after buying an additional 1,892,500 shares during the last quarter. Finally, State Street Corp grew its stake in shares of Taysha Gene Therapies by 49.1% during the 4th quarter. State Street Corp now owns 10,790,084 shares of the company’s stock worth $59,345,000 after acquiring an additional 3,553,619 shares during the period. Hedge funds and other institutional investors own 77.70% of the company’s stock.

Taysha Gene Therapies News Summary

Here are the key news stories impacting Taysha Gene Therapies this week:

• Positive Sentiment: Q4 2025 results topped expectations — reported EPS of ~$-0.087 vs. consensus ~$-0.096 and revenue of $5.49M well above estimates; management highlighted momentum on programs and financial results. Earnings Call Transcript (InsiderMonkey)
• Positive Sentiment: TSHA‑102 pivotal trial enrollment advancing and company says it’s on track to complete dosing in Q2 2026 with a 2026 BLA submission path — a clear clinical catalyst for future value. BLA Submission Path (MSN)
• Positive Sentiment: Analyst optimism picked up — Needham raised its price target to $12 (buy) and Chardan reaffirmed a $12 buy target, signaling sizable upside from current levels and likely contributing to increased attention. Analyst Coverage (Benzinga)
• Positive Sentiment: Company highlighted a strong cash position on the earnings call, which supports ongoing pivotal enrollment and development activity. Earnings Highlights (Yahoo Finance)
• Neutral Sentiment: Full earnings/management commentary and call transcripts are available from multiple outlets for investors who want the full details and Q&A. Transcript (Seeking Alpha)
• Negative Sentiment: Company remains unprofitable with a very negative net margin and negative return on equity; development risk and cash burn remain material risks until regulatory milestones or commercialization are achieved. Full Results & Corporate Update (GlobeNewswire)

About Taysha Gene Therapies

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.